Literature DB >> 1130403

Epidemiologic survey of rubella in a military recruit population.

R B Pollard, E A Edwards.   

Abstract

A seroepidemiologic surveillance of rubella infections in arriving male and female Navy recruits indicated that from 82-90% of young adults have hemagglutination (HA) titers of 1:10 or greater. Subsequent to the establishment of a new male recruit camp, there was a 10- to 11-month hiatus of low level rubella infection in the population. Once endemic rubella was established, more than 73.3 per cent of those with no detectable initial titer seroconverted. There was no reported rubella infection at an isolated female recruit camp of about 500 women even though the proportion of susceptibles was similar. However, once the female recruit camp was relocated within the male camp, their experience with rubella became comparable. A small (6.8% men, 5.6% women) number of recruits with pre-existing HA antibody titers had a four-fold or greater rise in titer during training. The great transmissibility of rubella virus in a closed population was illustrated and the ineffectiveness of herd immunity in this setting was evident.

Entities:  

Mesh:

Year:  1975        PMID: 1130403     DOI: 10.1093/oxfordjournals.aje.a112110

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  3 in total

1.  Public health implications of rubella antibody levels in California.

Authors:  L G Dales; J Chin
Journal:  Am J Public Health       Date:  1982-02       Impact factor: 9.308

2.  A rubella vaccination program for women entering the U.S. Army.

Authors:  S J Vaeth
Journal:  Public Health Rep       Date:  1979 Nov-Dec       Impact factor: 2.792

Review 3.  Description and utilization of the United States department of defense serum repository: a review of published studies, 1985-2012.

Authors:  Christopher L Perdue; Angelia A Eick Cost; Mark V Rubertone; Luther E Lindler; Sharon L Ludwig
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.